The Journal News

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

“Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in ...

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial ...
FiercePharma

Jaguar Animal Health Initiates Pivotal Field Study to Evaluate Safety and Effectiveness of Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and ...
AZ Central

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...
The Indianapolis Star

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia’s Indication to Treatment of General Diarrhea in Dogs

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia ®-CA1, is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple ...